Form 4: Boston Scientific CEO Sells Shares After Option Exercise

Boston Scientific's Chairman, President & CEO, Michael F. Mahoney, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-established 10b5-1 trading plan.

Summary

• Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corp (BSX), engaged in transactions involving the company's common stock.
• On February 2, 2026, Mahoney exercised options to acquire 49,407 shares at an exercise price of $24.55 per share.
• On the same date, he also exercised options to acquire 46,347 shares at an exercise price of $27.09 per share.
• Following these exercises, Mahoney sold 1,200 shares of common stock at a weighted average price of $94.0567 per share.
• Additionally, he sold 159,701 shares of common stock at a weighted average price of $93.4905 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2025.
• After these transactions, Mahoney directly beneficially owns 1,411,735 shares and indirectly owns 213,679 shares through a trust.
• He retains 231,739 stock options with an exercise price of $27.09 and an expiration date of February 15, 2028, and 98,814 stock options with an exercise price of $24.55 and an expiration date of February 28, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for an executive managing equity compensation and were executed under a pre-established 10b5-1 plan, indicating no new discretionary decision or change in sentiment regarding the company's prospects.

Positives

• The CEO exercised options at significantly lower prices ($24.55 and $27.09) compared to the sale prices ($93.49 to $94.13), indicating a substantial personal gain from long-term equity incentives.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which demonstrates planned, non-discretionary selling and helps mitigate concerns about opportunistic insider trading.

Negatives

• The CEO sold a significant number of shares (160,901 shares in total), which reduces his direct ownership stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives managing their personal portfolios and diversifying holdings. These transactions generally do not reflect a change in the company's fundamental outlook or the executive's confidence in the business, especially when part of a pre-scheduled plan.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO slightly reduces his direct ownership, but the overall impact on the company's stock price or long-term value is generally minimal given the pre-planned nature of the transaction.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Recommendation

The transactions reported are routine insider sales executed under a pre-established 10b5-1 plan, which typically do not signal a change in the company's fundamentals or the executive's long-term view. There is no new information in this filing that would warrant a change in investment thesis for Boston Scientific. Therefore, a 'hold' recommendation is appropriate as investors should rely on broader company performance and market conditions rather than these scheduled insider transactions.

Keywords

Boston Scientific, BSX, Michael F. Mahoney, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO Transactions, Equity Compensation